Scynexis Stock Price, News & Analysis

SCYNEXIS, Inc. has submitted a supplemental New Drug Application (sNDA) to the FDA for an additional indication of BREXAFEMME (ibrexafungerp) for preventing recurrent vulvovaginal candidiasis (RVVC). This follows positive data from the Phase 3 CANDLE study, where ibrexafungerp showed significant superiority over placebo, with 65.4% of patients achieving clinical success versus 53.1% in placebo (p=0.02). If approved, BREXAFEMME would be the first oral non-azole treatment for RVVC. The drug is generally safe, with mild adverse reactions.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced stock options grants totaling 23,000 shares to three new employees, incentivizing their acceptance of job offers. The options, priced at $2.11 per share, are part of SCYNEXIS' 2015 Inducement Award Plan. Each option has a ten-year term, with one-fourth of shares vesting after one year, followed by monthly vesting for three years, contingent on continued employment. SCYNEXIS focuses on innovative antifungal treatments, with its product BREXAFEMME recently approved by the FDA.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced that CEO Marco Taglietti will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami. The presentation will take place on May 25, 2022, from 11 a.m. to 11:30 a.m. EDT at Fontainebleau Miami Beach Hotel. SCYNEXIS is a biotechnology company focused on developing innovative treatments for difficult-to-treat and drug-resistant infections. Their lead product, BREXAFEMME^® (ibrexafungerp), received FDA approval on June 1, 2021. For more information, visit their website.

SCYNEXIS, a biotechnology firm, reported Q1 2022 financial results, with net revenues of $0.7 million from BREXAFEMME® (ibrexafungerp), launched in September 2021. The drug achieved nearly 4,000 prescriptions in the quarter and is covered by insurance plans representing 55% of commercially insured lives. The company initiated a global Phase 3 study (MARIO) for ibrexafungerp and reported positive interim results from trials, showing an 83.2% clinical response rate in patients. As of March 31, 2022, SCYNEXIS had $95.2 million in cash, projected to last into Q1 2024.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced positive interim results from the ongoing Phase 3 FURI study, showing that 71.4% of patients with refractory vulvovaginal candidiasis (VVC) treated with ibrexafungerp achieved successful clinical outcomes. Ibrexafungerp is effective for patients intolerant to standard antifungal therapies. The treatment was generally safe and well-tolerated. The company plans to submit a supplemental New Drug Application to the FDA based on positive findings from another study, furthering the potential for label expansion by year-end 2022.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced a conference call and webcast scheduled for May 12, 2022, at 8:30 a.m. ET, to discuss its first-quarter financial results for the period ended March 31, 2022. The live audio webcast will be accessible via SCYNEXIS's Investor Relations page, and a replay will be available for 90 days post-event. SCYNEXIS focuses on developing innovative antifungal therapies, with its lead product, ibrexafungerp, recently approved by the FDA and set for commercial launch in the U.S. under the brand name BREXAFEMME.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced a product theater presentation scheduled for May 7, 2022, at the ACOG Annual Meeting in San Diego. The focus will be on clinical data from the ongoing FURI study of ibrexafungerp, the first new antifungal class approved in over 25 years. The presentation will include outcomes from an open-label study addressing refractory vulvovaginal candidiasis. Ibrexafungerp shows promise as a broad-spectrum systemic antifungal, with FDA approvals and orphan drug designations supporting its innovative approach to treating drug-resistant infections.

SCYNEXIS announced positive interim results from its Phase 3 CARES study, showing a complete or partial response in 78% of 18 patients treated with ibrexafungerp for Candida auris infections, a significant pathogen linked to recent outbreaks. The data is consistent with previous studies for invasive candidiasis and candidemia. Additionally, new in vivo research supports ibrexafungerp's potential for treating mucormycosis, particularly during the COVID-19 pandemic. These findings underscore the urgent need for new therapies for drug-resistant infections.

SCYNEXIS, Inc. (Nasdaq: SCYX) has successfully closed a public offering, raising $45.0 million. The offering included 3,333,333 shares of common stock, along with pre-funded and traditional warrants. Shares were priced at $3.00 each, while pre-funded warrants were priced at $2.999. Additionally, the underwriters have a 30-day option to purchase up to 2,250,000 additional shares. The funds will support the company's continued development of its lead antifungal asset, ibrexafungerp, as they pursue market opportunities.